All In Biotech

Drug Trial Radar · NCT04834973

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanoma

Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

3

Actual

Start

May 7, 2021

Primary completion

Jul 12, 2022

Study completion Jul 12, 2022

Sponsor

Lead sponsor
QBiotics Group LimitedIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Apr 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase Ib/IIa, multicentre, open label, dose-escalation study to evaluate the safety, tolerability, and preliminary effectiveness of intratumoural tigilanol tiglate in combination with intravenous pembrolizumab in adult patients with unresectable, Stage IIIB to IV M1c melanoma.

Conditions

  • Melanoma

Interventions

  • tigilanol tiglateDrug

    Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2. Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours.

  • pembrolizumabDrug

    Three weekly 200 mg intravenous pembrolizumab treatment. Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine Dose LevelTime frame: 12 months
  2. Determine incidence of Treatment Emergent Adverse EventsTime frame: 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Melanoma Institute Australia

    Wollstonecraft, New South Wales, Australia

  • Cairns and Hinterland Hospital and Health Service

    Cairns, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.